CE Mark for IOL and delivery system

Article

Abbott Medical Optics (AMO) has announced the launch and CE Mark of approval for both the Tecnis multifocal toric IOL and iTec preloaded delivery system at the ESCRS in Milan this year.

Abbott Medical Optics (AMO) has announced the launch and CE Mark of approval for both the Tecnis multifocal toric IOL and iTec preloaded delivery system at the ESCRS in Milan this year.

The IOL is a premium lens solution for astigmatic cataract patients and provides spectacle-independence for the patient. It can also correct presbyopia and corneal astigmatism.

AMO also introduced the iTec preloaded delivery system, which allows the safe implantation of the IOL without having to manually load the lens. The delivery system is a highly-controlled, screw-style device providing reliability and efficiency for the surgeon.

Jim Mazzo, senior vice president of AMO, stated, "Cataract surgeons in Europe now have two new products available to address the unique lifestyle needs of their patients, By receiving CE Mark for the TECNIS Multifocal Toric IOL and the TECNIS iTec Preloaded Delivery System, Abbott continues to demonstrate its commitment to advancing cataract vision care innovation and providing high quality patient outcomes."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.